Magnolia Medical Technologies, Inc.
Magnolia Medical is dedicated to delivering innovative solutions that improve diagnostic accuracy for sepsis testing, support better clinical decisions, and enhance patient outcomes. Their mission is to create new standards in blood culture collection by reducing contamination and false positives, thereby preventing unnecessary treatments and costs. They develop evidence-backed products like the Steripath® Initial Specimen Diversion Device® to achieve these goals and are committed to industry-leading practices and continuous innovation.
Industries
Nr. of Employees
medium (51-250)
Magnolia Medical Technologies, Inc.
1800 116th Ave NE, Suite 200, Bellevue, WA 98004
Patents
Systems and methods for delivering a fluid to a patient with reduced contamination
US-12133968-B2
View Details
Systems and methods for delivering a fluid to a patient with reduced contamination
US-12133968-B2
View DetailsProducts
Initial specimen diversion device for blood culture collection (standard configuration)
A single-use device configured to divert and sequester the initial specimen volume during blood culture collection to reduce contamination and false-positive results.
Small-configuration initial specimen diversion device for peripheral micro/needle collection
A micro-configuration of the specimen diversion device designed to support small-gauge peripheral sticks and direct-to-media peripheral IV starts for patients where smaller collection sets are used.
Steripath Clinical & Economic Evidence Report (evidence synthesis)
A compiled report summarizing multiple clinical studies and economic analyses demonstrating clinical outcomes, contamination-rate reductions, and cost impacts associated with adoption of specimen diversion technology.
Initial specimen diversion device for blood culture collection (standard configuration)
A single-use device configured to divert and sequester the initial specimen volume during blood culture collection to reduce contamination and false-positive results.
Small-configuration initial specimen diversion device for peripheral micro/needle collection
A micro-configuration of the specimen diversion device designed to support small-gauge peripheral sticks and direct-to-media peripheral IV starts for patients where smaller collection sets are used.
Steripath Clinical & Economic Evidence Report (evidence synthesis)
A compiled report summarizing multiple clinical studies and economic analyses demonstrating clinical outcomes, contamination-rate reductions, and cost impacts associated with adoption of specimen diversion technology.
Services
Analytics service to capture clinical data and quantify clinical and cost effectiveness of interventions that reduce diagnostic errors and false-positive blood culture results.
Online course platform offering modular training on blood culture collection, evidence-based best practices, progress tracking and continuing-education credit eligibility.
On-site and remote implementation services including training, protocol development, and sustainment planning to integrate diversion techniques into hospital workflows and reduce contamination rates.
Analytics service to capture clinical data and quantify clinical and cost effectiveness of interventions that reduce diagnostic errors and false-positive blood culture results.
Online course platform offering modular training on blood culture collection, evidence-based best practices, progress tracking and continuing-education credit eligibility.
On-site and remote implementation services including training, protocol development, and sustainment planning to integrate diversion techniques into hospital workflows and reduce contamination rates.
Expertise Areas
- Diagnostic stewardship for bloodstream infection testing
- Blood culture contamination reduction
- Clinical study design and outcomes research
- Antimicrobial stewardship support through diagnostic accuracy
Key Technologies
- Initial specimen diversion technique for blood collection
- Device-based blood diversion and sequestration methods
- Clinical outcomes and health-economic modeling
- Web-based learning management and CE delivery
News & Updates
April 11, 2023 - Announcement of FDA clearance for expanded configurations of Steripath Micro.
February 8, 2023 - NQF endorsement of CDC’s new blood culture contamination quality measure.
January 24, 2023 - Study showing a 74% increase in in-hospital mortality risk due to blood culture contamination.
February 18, 2025 - Emphasizes the importance of following evidence-based practices for blood culture collection.
January 22, 2025 - Discusses the clinical and economic impacts of false-positive blood cultures.
Multiple peer-reviewed studies demonstrating contamination rate reductions of 75-100% using Steripath.
April 11, 2023 - Announcement of FDA clearance for expanded configurations of Steripath Micro.
February 8, 2023 - NQF endorsement of CDC’s new blood culture contamination quality measure.
January 24, 2023 - Study showing a 74% increase in in-hospital mortality risk due to blood culture contamination.
February 18, 2025 - Emphasizes the importance of following evidence-based practices for blood culture collection.
January 22, 2025 - Discusses the clinical and economic impacts of false-positive blood cultures.
Multiple peer-reviewed studies demonstrating contamination rate reductions of 75-100% using Steripath.